What are CorMedix's total assets?

CorMedix (CRMD) holds $815.6M in total assets, up 445.3% year over year.

How much cash does CorMedix have?

CorMedix holds $179.1M in cash and equivalents.

Can CorMedix cover its short-term obligations?

Its current ratio is 2.98 — current assets exceed current liabilities.

Where does CorMedix's balance sheet data come from?

Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

CorMedix CRMD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$179.08M+22.8%	$145.83M+195%	$49.48M-69.0%	$159.41M+140%	$66.39M+62.9%
Short-term investments	$0-100%	$3.69M-48.9%	$7.22M-77.0%	$31.4M+180%	$11.22M+1.6%
Restricted cash	$656K+97.6%	$332K-66.4%	$988.23K+840%	$105.08K—	$0-100%
Accounts receivable, net	$154.81M-9.6%	$171.23M+8.0%	$158.57M+270%	$42.91M-21.4%	$54.61M—
Inventories	$30.73M+3.4%	$29.72M+2.8%	$28.92M+200%	$9.63M+28.7%	$7.49M-1.5%
Raw materials	$6.22M+71.1%	$3.64M-48.2%	$7.02M+531%	$1.11M+0.2%	$1.11M-0.1%
Work in process	$9.23M-21.1%	$11.69M+28.7%	$9.08M+74.6%	$5.2M+21.4%	$4.28M+21.4%
Finished goods	$15.29M+6.2%	$14.39M+12.3%	$12.82M+286%	$3.32M+58.5%	$2.09M-29.3%
Prepaid expenses and other current assets	$19.49M+10.9%	$17.57M+7.6%	$16.33M+249%	$4.68M-8.8%	$5.12M+41.1%
Total current assets	$383.11M+4.4%	$367.05M+41.4%	$259.54M+4.6%	$248.06M+71.2%	$144.86M+26.4%
Property and equipment, net	$6.17M+3.5%	$5.96M+37.1%	$4.35M+165%	$1.64M-5.0%	$1.73M-5.5%
Goodwill	——	——	——	——	——
Intangible assets, net	$368.77M-2.7%	$379.07M+48.9%	$254.61M+14,531%	$1.74M—	——
Other non-current assets	$24.27M-12.6%	$27.78M+21.2%	$22.91M—	——	——
Total assets	$815.64M-1.3%	$826.14M+10.0%	$750.86M+197%	$252.6M+68.9%	$149.58M+25.9%
Accounts payable	$12.83M+62.7%	$7.88M-61.5%	$20.45M+252%	$5.82M+201%	$1.93M+12.4%
Accrued expenses	$112.77M-31.0%	$163.37M+49.8%	$109.09M+324%	$25.72M+10.5%	$23.27M-27.2%
Income taxes payable	$16.84M—	——	——	——	——
Accrued interest	——	——	——	——	——
Total current liabilities	$128.78M-26.1%	$174.27M+30.4%	$133.64M+321%	$31.71M-7.8%	$34.39M+1.6%
Deferred tax liabilities	——	——	——	——	——
Other non-current liabilities	——	——	——	——	——
Total liabilities	$378.59M-10.0%	$420.84M+11.7%	$376.73M+1,078%	$31.97M-7.9%	$34.69M+1.5%
Preferred stock	$0—	$0-100%	$920.0%	$920.0%	$92-32.8%
Common stock	160M0.0%	160M0.0%	160M0.0%	160M0.0%	160M0.0%
Additional paid-in capital	$574.94M-1.2%	$581.8M+3.1%	$564.56M+8.6%	$519.63M+19.8%	$433.72M+2.3%
Retained earnings	-$137.97M+21.9%	-$176.58M+7.4%	-$190.6M+36.3%	-$299.16M+6.2%	-$318.99M+6.1%
Accumulated other comprehensive income (loss)	$2K-33.3%	$3K-96.6%	$87.64K+10.3%	$79.44K-6.1%	$84.56K-7.1%
Total stockholders' equity	$437.05M+7.8%	$405.31M+8.3%	$374.13M+69.6%	$220.63M+92.0%	$114.89M+35.7%
Total liabilities and stockholders' equity	$815.64M-1.3%	$826.14M+10.0%	$750.86M+197%	$252.6M+68.9%	$149.58M+25.9%
Available-for-Sale Debt Securities - Amortized Cost	——	$8.5M+1.0%	$8.41M-87.0%	$64.94M+88.2%	$34.51M+1.1%
Cash, Cash Equivalents, and Marketable Securities	——	$8.5M+1.0%	$8.42M-87.0%	$64.94M+88.1%	$34.51M+1.0%
Contract Assets, Net	——	——	——	——	——
Net Assets Acquired in Business Combination	——	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	——	——	——	——	——
Deferred Tax Assets - Tax Credit Carryforwards	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——	——
Investments - Amortized Cost Basis	——	$8.5M+1.0%	$8.41M-87.0%	$64.94M+88.2%	$34.51M+1.1%
Net Operating Loss Carryforwards	——	——	——	——	——
Deferred tax assets	——	——	——	——	——
Other intangible assets—net	$368.77M-2.7%	$379.07M-2.8%	$390.01M+22,311%	$1.74M—	——
Strategic investments	——	——	——	——	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$0-100%	$3.69M-48.9%	$7.22M-77.0%	$31.4M+180%	$11.22M+1.6%
Other Investments	——	——	——	——	——
Other Commercial Liabilities	$112.77M-31.0%	$163.37M+49.8%	$109.09M+324%	$25.72M-20.3%	$32.28M+1.0%
Accrued Liabilities, Current	$112.77M-31.0%	$163.37M+49.8%	$109.09M+324%	$25.72M-20.3%	$32.28M+1.0%
Contingent Consideration, short-term	——	——	——	——	——
Professional Service Fees Payable	$5.85M-6.6%	$6.26M+5.4%	$5.94M+150%	$2.37M+35.3%	$1.75M+103%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	78.4M-1.1%	79.3M+1.2%	78.3M+5.0%	74.6M+10.2%	67.7M+5.1%
Convertible Preferred Stock Authorized Shares	2M0.0%	2M0.0%	2M0.0%	2M0.0%	2M0.0%
Convertible Preferred Stock Issued Shares	91.6K0.0%	91.6K0.0%	91.6K0.0%	91.6K0.0%	91.6K-32.9%
Convertible Preferred Stock Outstanding Shares	91.6K0.0%	91.6K0.0%	91.6K0.0%	91.6K0.0%	91.6K-32.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$78K-1.3%	$79K+0.8%	$78.35K+5.0%	$74.62K+10.2%	$67.71K+5.8%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0-100%	$920.0%	$920.0%	$92-32.8%
Preferred Stock Liquidation Preference Value	$5.64M0.0%	$5.64M0.0%	$5.64M+27.4%	$4.43M0.0%	$4.43M-65.6%
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share Price	——	——	——	——	——
Share Repurchase Authorization Limit	——	——	——	——	——
Unrealized Gains on Investments	——	$0-100%	$3.69K+135%	$1.57K+2,432%	$62-98.5%
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Cumulative Cost Basis	——	$8.5M+1.0%	$8.41M-87.0%	$64.94M+88.2%	$34.51M+1.1%
Accounts Receivable, after Allowance for Credit Loss	——	——	——	——	——
Employee payroll tax withheld on employee stock transactions	$5.77M-65.8%	$16.85M-11.3%	$19M+422%	$3.64M+41.2%	$2.58M-60.6%
Professional service fees	$5.85M-6.6%	$6.26M+5.4%	$5.94M+150%	$2.37M+35.3%	$1.75M+103%
Accrued sales allowances	——	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	$0-100%	$3.69K+135%	$1.57K+2,432%	$62-98.5%
Total	——	$8.5M+1.0%	$8.41M-87.0%	$64.94M+88.2%	$34.51M+1.1%
Available for sale investments	——	$8.5M+1.0%	$8.42M-87.0%	$64.94M+88.1%	$34.51M+1.0%
Net assets acquired	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$160M0.0%	$160M0.0%	$160M0.0%	$160M0.0%	$160M0.0%
Common stock, shares issued (in shares)	$78.4M-1.1%	$79.26M+1.2%	$78.35M+5.0%	$74.62M+10.2%	$67.71M+5.1%
Common Stock, Shares, Outstanding	$78.4M-1.1%	$79.26M+1.2%	$78.35M+5.0%	$74.62M+10.2%	$67.71M+5.1%
Contingent Consideration, net of current portion	——	——	——	——	——
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred Tax Assets Capitalized Licensing Fees	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets Interest Expense	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	——	——	——	——
U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	——	——	——	——	——
Deferred Tax Assets Sales Return	——	——	——	——	——
Deferred Tax Assets Section One Seventy Four Capitalization	——	——	——	——	——
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Accrued Compensation	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
R&D capitalization	——	——	——	——	——
Federal and state intangible assets	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——	——
Raw materials	$6.22M+71.1%	$3.64M-48.2%	$7.02M+531%	$1.11M+0.2%	$1.11M-0.1%
Manufacturing related	$2.08M+281%	$546K-49.2%	$1.07M+317%	$257.51K+15.2%	$223.58K-61.0%
Operating Loss Carryforwards	——	——	——	——	——
Operating Loss Carryforwards Valuation Allowance	——	——	——	——	——
Other accrued liabilities	$4.63M+1.9%	$4.55M+1,531%	$278.68K+104%	$136.3K+55.9%	$87.42K-29.5%
Other Commitment	——	——	——	——	——
Other long term assets of restricted cash	——	——	——	——	——
Preferred stock, liquidation preference, value	$5.64M0.0%	$5.64M0.0%	$5.64M+27.4%	$4.43M0.0%	$4.43M-65.6%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$2M0.0%	$2M0.0%	$2M0.0%	$2M0.0%	$2M0.0%
Preferred Stock, Shares Issued	$91.62K0.0%	$91.62K0.0%	$91.62K0.0%	$91.62K0.0%	$91.62K-32.9%
Preferred Stock, Shares Outstanding	$91.62K0.0%	$91.62K0.0%	$91.62K0.0%	$91.62K0.0%	$91.62K-32.9%
Prepaid expenses and other current assets of restricted cash	——	——	——	——	——
Restricted cash equivalents included in Other long-term assets	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	——	——	——	——	——
Share price (in dollars per share)	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares	——	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——	——
Purchase Obligation	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CorMedix.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are CorMedix's total assets?: CorMedix (CRMD) holds $815.6M in total assets, up 445.3% year over year.
How much cash does CorMedix have?: CorMedix holds $179.1M in cash and equivalents.
Can CorMedix cover its short-term obligations?: Its current ratio is 2.98 — current assets exceed current liabilities.
Where does CorMedix's balance sheet data come from?: Every line is extracted from CorMedix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.